Flow cytometry finds elevated CTLA4 and T-cell dysfunction in myelodysplastic neoplasms with TP53 mutations, indicating therapeutic targets for immune modulation.
Key Points
MDS patients with TP53 mutations exhibit significant T-cell dysfunction, evident by an increase in exhausted T-cell subsets.
Flow cytometry revealed high frequencies of CTLA4+, PD-1+, and Treg cells in TP53-mutated MDS compared to controls.
Single-cell RNA sequencing analysis confirmed elevated inhibitory receptor expression on CD8+ and CD4+ T cells in TP53-mutated cases.
Targeting checkpoint receptors may provide new immunomodulatory strategies for TP53-mutant MDS treatment.